Surgical management of intrahepatic cholangiocarcinoma

References

• Beal EW, Tumin D, Moris D, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2018 Aug;7(4):270–276.
   PubMed Web of Science ®Google Scholar
• Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: Facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019 07; 43(7): 1777–1787.
   PubMed Web of Science ®Google Scholar
• Precursor GB. Lesions of cholangiocarcinoma: A clinicopathologic review. Clin Pathol. 2020 Jan-Dec;13:2632010X20925045.
   PubMed Web of Science ®Google Scholar
• Klöppel G, Adsay V, Konukiewitz B, et al. Precancerous lesions of the biliary tree. Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):285–297.
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Shimizu H, Kato A, et al. Intraductal papillary neoplasms of the bile duct. Int J Hepatol. 2014;2014:459091.
   PubMedGoogle Scholar
• Wan XS, et al. Intraductal papillary neoplasm of the bile duct. World J Gastroenterol. 2013 Dec 14;19(46):8595–8604.
   PubMed Web of Science ®Google Scholar
• Khan SA, Tavolari S, Cholangiocarcinoma: Bg. epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.
   PubMedGoogle Scholar
• Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020 june 01;126(11):2666–2678.
   PubMed Web of Science ®Google Scholar
• Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014 Apr;23(2):231–246.
   PubMed Web of Science ®Google Scholar
• Van Dyke AL, Shiels MS, Jones GS, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer. 2019 may 01;125(9):1489–1498.
   PubMed Web of Science ®Google Scholar
• Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77–82.
   PubMed Web of Science ®Google Scholar
• Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004 Mar;40(3):472–477.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb;15(2):95–111.
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019 july;71(1):104–114.
   PubMed Web of Science ®Google Scholar
• Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002 May;03(2):10.
   Google Scholar
• Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002 Dec;37(6):806–813.
   PubMed Web of Science ®Google Scholar
• Howlader NNA, Krapcho M, Miller D, et al., eds. SEER Cancer Statistics Review. Bethesda: National Cancer Institute; 1975-2017.
   Google Scholar
• Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018 06; 105(7): 848–856.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013 Apr;29(4):1259–1267.
   PubMed Web of Science ®Google Scholar
• Coon C, Berger N, Eastwood D, et al. Primary Liver Cancer: an NCDB Analysis of Overall Survival and Margins After Hepatectomy. Ann Surg Oncol. 2020 Apr;27(4):1156–1163.
   PubMed Web of Science ®Google Scholar
• Lee GC, Gamblin TC, Fong ZV, et al. Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019 Nov;26(12):4091–4099.
   PubMed Web of Science ®Google Scholar
• Kennedy L, Hargrove L, Demieville J, et al. Recent Advances in Understanding Cholangiocarcinoma. F1000Res. 2017;6:1818.
   PubMedGoogle Scholar
• Blechacz B, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011 8; Aug(9): 512–522.
   Google Scholar
• El Rassi ZE, Partensky C, Scoazec JY, et al. Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management. Eur J Surg Oncol. 1999 Aug;25(4):375–380.
   PubMedGoogle Scholar
• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007 May;245(5):755–762.
   PubMed Web of Science ®Google Scholar
• El-Diwany R, Pawlik TM, Intrahepatic cholangiocarcinoma ea. Surgical oncology clinics of North America. 2019 Oct;28(4):587–599.
   PubMed Web of Science ®Google Scholar
• Tao LY, Cai L, He XD, et al. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010 Nov;76(11):1210–1213.
   PubMed Web of Science ®Google Scholar
• Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005 Sep;50(9):1734–1740.
   PubMed Web of Science ®Google Scholar
• Moro A, Mehta R, Sahara K, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020 Aug;27(8):2888–2901.
   PubMed Web of Science ®Google Scholar
• Fábrega-Foster K, Ghasabeh MA, Pawlik TM, et al. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017 Apr;6(2):67–78.
   PubMed Web of Science ®Google Scholar
• Liu GJ, Wang W, Lu MD, et al. Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Liver Cancer. 2015 Dec;4(4):241–252.
   PubMed Web of Science ®Google Scholar
• Valls C, Gumà A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000 Sep-Oct;25(5):490–496.
   PubMedGoogle Scholar
• Seo N, Kim DY, Choi JY. Cross-sectional imaging of intrahepatic cholangiocarcinoma: Development, growth, spread, and prognosis. AJR Am J Roentgenol. 2017 Aug;209(2):W64–W75.
   PubMed Web of Science ®Google Scholar
• Blechacz B. Cholangiocarcinoma: Current knowledge and new developments. Gut Liver. 2017 Jan 15;11(1):13–26.
   PubMed Web of Science ®Google Scholar
• Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. Eur Radiol. 2017 Feb;27(2):498–506.
   PubMed Web of Science ®Google Scholar
• Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology. 2009 Sep;50(3):791–798.
   PubMed Web of Science ®Google Scholar
• Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008 Jan;206(1):57–65.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471–1474.
   PubMed Web of Science ®Google Scholar
• Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009 Jan;16(1):14–22.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition ajcc cancer staging manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017 Mar;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol. 2018 Oct;7(5):52.
   PubMed Web of Science ®Google Scholar
• Yuan L, Luo X, Lu X, et al. Liver resection for intrahepatic cholangiocarcinoma in AJCC‑stage Ⅳ: An evaluation of the survival benefit and prognostic accuracy of current AJCC staging system on N and M classification. Oncol Rep. 2016 Nov;36(5):2663–2672.
   PubMed Web of Science ®Google Scholar
• Kim Y, Moris DP, Zhang XF, et al. Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol. 2017 Nov;116(6):643–650.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American joint committee on cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017 May;115(6):696–703.
   PubMed Web of Science ®Google Scholar
• Kang SH, Hwang S, Lee YJ, et al. Prognostic comparison of the 7th and 8th editions of the American joint committee on cancer staging system for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2018 Apr;25(4):240–248.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Margonis GA, Andreatos N, et al. Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford). 2018 10; 20(10): 956–965.
   PubMed Web of Science ®Google Scholar
• Uenishi T, Ariizumi S, Aoki T, et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the study group for hepatic surgery of the Japanese society of hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci. 2014 Jul;21(7):499–508.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Lei Z, Si A, et al. Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers. HPB (Oxford). 2019 12;21(12):1656–1666.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Xue F, He J, et al. Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. HPB (Oxford). 2021 Mar 18.
   Web of Science ®Google Scholar
• Ma K, Dong B, Wang L, et al. Nomograms for predicting overall survival and cancer-specific survival in patients with surgically resected intrahepatic cholangiocarcinoma. Cancer Manag Res. 2019;11:6907–6929.
   PubMed Web of Science ®Google Scholar
• Shen H, Zhang S, Xia Y, et al. A nomogram in predicting risks of intrahepatic cholangiocarcinoma after partial hepatectomy for hepatolithiasis. J Gastrointest Surg. 2021 Feb 09;25(9):2258–2267.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013 Mar 20;31(9):1188–1195.
   PubMed Web of Science ®Google Scholar
• Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014 May;149(5):432–438.
   PubMed Web of Science ®Google Scholar
• Ebata T, Kosuge T, Hirano S, et al. Proposal to modify the International Union against cancer staging system for perihilar cholangiocarcinomas. Br J Surg. 2014 Jan;101(2):79–88.
   PubMed Web of Science ®Google Scholar
• D’Angelica M, Fong Y, Weber S, et al. The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann Surg Oncol. 2003 Mar;10(2):183–189.
   PubMed Web of Science ®Google Scholar
• Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001 Oct;193(4):384–391.
   PubMed Web of Science ®Google Scholar
• Weber SM, Ribero D, O’Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015 Aug;17(8):669–680.
   PubMed Web of Science ®Google Scholar
• Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc. 2006 May;20(5):721–725.
   PubMed Web of Science ®Google Scholar
• Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006 Mar;243(3):364–372.
   PubMed Web of Science ®Google Scholar
• van den Broek MA, Olde Damink SW, Dejong CH, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int. 2008 Jul;28(6):767–780.
   PubMed Web of Science ®Google Scholar
• Chakedis J, Squires MH, Beal EW, et al. Update on current problems in colorectal liver metastasis. Curr Probl Surg. 2017 Nov;54(11):554–602.
   PubMed Web of Science ®Google Scholar
• Shindoh J, Tzeng CW, Aloia TA, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013 Aug;20(8):2493–2500.
   PubMed Web of Science ®Google Scholar
• Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007 Mar;94(3):274–286.
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002 Jun;1376:675–680. discussion 680-1.
   PubMedGoogle Scholar
• Abdalla EK. Resection of colorectal liver metastases. J Gastrointest Surg. 2011 Mar;15(3):416–419.
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000 May;127(5):512–519.
   PubMed Web of Science ®Google Scholar
• Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997 Nov;26(5):1176–1181.
   PubMed Web of Science ®Google Scholar
• Thirunavukarasu P, Aloia TA. Preoperative assessment and optimization of the future liver remnant. Surg Clin North Am. 2016 Apr;96(2):197–205.
   PubMed Web of Science ®Google Scholar
• Hoekstra LT, de Graaf W, Nibourg GA, et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg. 2013 Jan;257(1):27–36.
   PubMed Web of Science ®Google Scholar
• Simpson AL, Geller DA, Hemming AW, et al. Liver planning software accurately predicts postoperative liver volume and measures early regeneration. J Am Coll Surg. 2014 Aug;219(2):199–207.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Plass I, Fitschek F, et al. The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection. Sci Rep. 2019 june 10;9(1):8421.
   PubMedGoogle Scholar
• Haegele S, Reiter S, Wanek D, et al. Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection. PLoS One. 2016;11(11):e0165481.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Yan XL, Li J, et al. Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis. Cancer Manag Res. 2020;12:3237–3245.
   PubMed Web of Science ®Google Scholar
• Ribero D, Chun YS, Vauthey JN. Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol. 2008 Jun;25(2):104–109.
   PubMedGoogle Scholar
• Kosuge T, Makuuchi M, Takayama T, et al. [Preoperative portal embolization increases safety of hepatectomy]. Nihon Geka Gakkai Zasshi. 1991Sep; 929: 1320–1323
   PubMedGoogle Scholar
• Cieslak KP, Huisman F, Bais T, et al. Future remnant liver function as predictive factor for the hypertrophy response after portal vein embolization. Surgery. 2017 07; 162(1): 37–47.
   PubMed Web of Science ®Google Scholar
• Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011 Nov;2545:824–829. discussion 830.
   PubMed Web of Science ®Google Scholar
• Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis of 434 patients. Arch Surg. 2012 Dec;147(12):1107–1113.
   PubMedGoogle Scholar
• Shimada K, Sano T, Sakamoto Y, et al. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol. 2007 Aug;96(2):160–165.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015 Nov;22(12):4020–4028.
   PubMed Web of Science ®Google Scholar
• Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008 Oct;15(10):2787–2794.
   PubMed Web of Science ®Google Scholar
• Ali SM, Clark CJ, Zaydfudim VM, et al. Role of major vascular resection in patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2013 Jun;20(6):2023–2028.
   PubMed Web of Science ®Google Scholar
• Reames BN, Ejaz A, Koerkamp BG, et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. J Surg Oncol. 2017 Aug;116(2):133–139.
   PubMed Web of Science ®Google Scholar
• Esaki M, Shimada K, Nara S, et al. Left hepatic trisectionectomy for advanced perihilar cholangiocarcinoma. Br J Surg. 2013 May;100(6):801–807.
   PubMed Web of Science ®Google Scholar
• Hosokawa I, Shimizu H, Yoshitomi H, et al. Outcomes of left trisectionectomy and right hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford). 2019 04; 21(4): 489–498.
   PubMed Web of Science ®Google Scholar
• Matsumoto N, Ebata T, Yokoyama Y, et al. Role of anatomical right hepatic trisectionectomy for perihilar cholangiocarcinoma. Br J Surg. 2014 Feb;101(3):261–268.
   PubMed Web of Science ®Google Scholar
• Matsuoka L, Alexopoulos S, Petrovik L, et al. Trisectionectomy for cholangiocarcinoma: is it worth it? Am Surg. 2014 Jun;80(6):544–548.
   PubMed Web of Science ®Google Scholar
• Ebata T, Yokoyama Y, Igami T, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg. 2012 Aug;256(2):297–305.
   PubMed Web of Science ®Google Scholar
• Zhou R, Lu D, Li W, et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis. HPB (Oxford). 2019 07; 21(7): 784–792.
   PubMed Web of Science ®Google Scholar
• Network NCC Hepatobiliary Cancers v2. 2021 June 12. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
   Google Scholar
• Zhang XF, Lv Y, Weiss M, et al. Should utilization of lymphadenectomy vary according to morphologic subtype of intrahepatic cholangiocarcinoma? Ann Surg Oncol. 2019 Jul;26(7):2242–2250.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Chen Q, Kimbrough CW, et al. lymphadenectomy for intrahepatic cholangiocarcinoma: has nodal evaluation been increasingly adopted by surgeons over time?A national database analysis. J Gastrointest Surg. 2018 04;22(4):668–675.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Chakedis J, Bagante F, et al. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. Br J Surg. 2018 06; 105(7): 857–866.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Xue F, Dong DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis. Ann Surg. 2020 Jan 14.
   Web of Science ®Google Scholar
• Martin SP, Drake J, Wach MM, et al. Laparoscopic approach to intrahepatic cholangiocarcinoma is associated with an exacerbation of inadequate nodal staging. Ann Surg Oncol. 2019 Jun;26(6):1851–1857.
   PubMed Web of Science ®Google Scholar
• Kim SH, Han DH, Choi GH, et al. Extent of lymph node dissection for accurate staging in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2021 Jun 7. https://doi.org/10.1007/s11605-021-05039-5.
   Google Scholar
• Tsilimigras DI, Hyer JM, Paredes AZ, et al. Tumor burden dictates prognosis among patients undergoing resection of intrahepatic cholangiocarcinoma: A tool to guide post-resection adjuvant chemotherapy? Ann Surg Oncol. 2021 Apr;28(4):1970–1978.
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Mehta R, Aldrighetti L, et al. Development and validation of a laboratory risk score (labscore) to predict outcomes after resection for intrahepatic cholangiocarcinoma. J Am Coll Surg. 2020 04; 230(4): 381–391.e2.
   PubMedGoogle Scholar
• Tsilimigras DI, Hyer JM, Paredes AZ, et al. A novel classification of intrahepatic cholangiocarcinoma phenotypes using machine learning techniques: An international multi-institutional analysis. Ann Surg Oncol. 2020 Dec;27(13):5224–5232.
   PubMed Web of Science ®Google Scholar
• Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis. JAMA Surg. 2014 Jun;149(6):565–574.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou Y, Hu K, et al. Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study. BMC Cancer. 2020 Mar 30;20(1):270.
   PubMed Web of Science ®Google Scholar
• Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol. 2014 Aug;27(8):1163–1173.
   PubMed Web of Science ®Google Scholar
• Ejaz A, Sachs T, He J, et al. A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. Surgery. 2014 Sep;156(3):538–547.
   PubMed Web of Science ®Google Scholar
• Wu J, Han J, Zhang Y, et al. Safety and feasibility of laparoscopic versus open liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma. Biosci Trends. 2020 Nov 04;14(5):376–383.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Song J, Xu X, et al. Safety and feasibility of laparoscopic liver resection for patients with large or multiple intrahepatic cholangiocarcinomas: a propensity score based case-matched analysis from a single institute. Medicine (Baltimore). 2019 Dec;98(49):e18307.
   PubMed Web of Science ®Google Scholar
• Lee W, Park JH, Kim JY, et al. Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma. Surg Endosc. 2016 Nov;30(11):4835–4840.
   PubMed Web of Science ®Google Scholar
• Wei F, Wang G, Ding J, et al. Is it time to consider laparoscopic hepatectomy for intrahepatic cholangiocarcinoma? A meta-analysis. J Gastrointest Surg. 2020 10; 24(10): 2244–2250.
   PubMed Web of Science ®Google Scholar
• Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018 02;24(2):294–303.
   PubMed Web of Science ®Google Scholar
• Becker NS, Rodriguez JA, Barshes NR, et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg. 2008 Jan;12(1):117–122.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, De Lope CR, Gastaca M, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A Spanish matched cohort multicenter study. Ann Surg. 2014 May;259(5):944–952.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016 10; 64(4): 1178–1188.
   PubMed Web of Science ®Google Scholar
• Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: A 24-year experience in a single center. Arch Surg. 2011 Jun;146(6):683–689.
   PubMedGoogle Scholar
• Takahashi K, Obeid J, Burmeister CS, et al. Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis. Ann Transplant. 2016 Apr;12(21):208–215.
   Google Scholar
• Squires MH, Cloyd JM, Dillhoff M, et al. Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):671–681.
   PubMed Web of Science ®Google Scholar
• Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013 Jun;153(6):811–818.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016 Jan;23(1):235–243.
   PubMed Web of Science ®Google Scholar
• Akateh C, Ejaz AM, Pawlik TM, et al. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol. 2020 Oct 27;12(10):693–708.
   PubMed Web of Science ®Google Scholar
• Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018 Jun;105(7):839–847.
   PubMed Web of Science ®Google Scholar
• Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015 Dec;22(Suppl 3):S1093–9.
   PubMed Web of Science ®Google Scholar
• Maithel SK Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer ClinicalTrials.gov Identifier: NCT03579771. Available from: https://clinicaltrials.gov/ct2/show/NCT03579771
   Google Scholar
• Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020 Oct;27(10):3729–3737.
   PubMed Web of Science ®Google Scholar
• Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013 Nov;20(12):3779–3786.
   PubMed Web of Science ®Google Scholar
• Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016 Mar 01;122(5):758–765.
   PubMed Web of Science ®Google Scholar
• Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2020 Jan 01;6(1):60–67.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014 Jun;60(6):1268–1289.
   PubMed Web of Science ®Google Scholar
• Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase iii study. J Clin Oncol. 2019 Mar 10;37(8):658–667.
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 05; 20(5): 663–673.
   PubMed Web of Science ®Google Scholar
• Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015 Jul 31;15:564.
   PubMed Web of Science ®Google Scholar
• Nakachi K, Konishi M, Ikeda M, et al. A randomized phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: japan clinical oncology group study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018 Apr 01;48(4):392–395.
   PubMed Web of Science ®Google Scholar
• Sicklick JK, Fanta PT, Shimabukuro K, et al. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 Jun;35(2):263–275.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019 Aug;10(4):652–662.
   PubMed Web of Science ®Google Scholar
• Czauderna C, Kirstein MM, Tews HC, et al. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. In J Clin Med. Vol. 10. Jun 25; 2021. p. 13.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796–807.
   PubMed Web of Science ®Google Scholar
• Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017 Jul;22(7):804–810.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006 Aug 15;66(16):8109–8115.
   PubMed Web of Science ®Google Scholar
• Xie Y, Jiang Y, Yang XB, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: a case report. World J Gastroenterol. 2016 Dec 14;22(46):10254–10259.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006 Jul 1;24(19):3069–3074.
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010 Jul 20;28(21):3491–3497.
   PubMed Web of Science ®Google Scholar
• Kim ST, Jang KT, Lee SJ, et al. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer. 2015 Jul 21;15:530.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017 Jul 28;357(6349):409–413.
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Bezu L, Gomes-de-Silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Koyama T, Helwig C, et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with advanced solid tumors. J clin oncol. 2018;36(4_suppl):762.
   Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020 Jun 1;6(6):888–894.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 Oct 15;147(8):2190–2198.
   PubMed Web of Science ®Google Scholar
• Lwin Z, Gomez-Roca C, Saada-Bouzid E, et al. LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Ann Oncol. 2020;31:S1170.
   Web of Science ®Google Scholar
• Diggs LP, Ruf B, Ma C, et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J Hepatol. 2021 May;74(5):1145–1154.
   PubMed Web of Science ®Google Scholar
• Wabitsch S, Tandon M, Ruf B, et al. Anti-PD-1 in combination with trametinib suppresses tumor growth and improves survival of intrahepatic cholangiocarcinoma in mice. Cell Mol Gastroenterol Hepatol. 2021;12(3):1166–1178.
   PubMed Web of Science ®Google Scholar